Sirio Pharma’s Strong Performance with Impressive Overseas Growth

Sirio Pharma released its performance report for the first half of 2023. Sirio Pharma achieved an operating income of RMB 1.545 billion yuan (USD $210 million), with a year-on-year growth of 39%. It’s worth noting that its overseas business generated sales revenue of RMB 747 million yuan (USD $102 million), marking a significant year-on-year growth of 71.82%.

In January 2023, Sirio Pharma announced the completion of its acquisition of Best Formulation. Following the merger, the company’s operations in the Americas region saw a remarkable year-on-year growth of 101.7%. In April of this year, Sirio Pharma’s cross-border bonded factory in the Zhuhai-Macao Cross-Border Zone was officially launched, aiming to leverage the international industrial chain cooperation and serve as a hub for cross-border trade. (Source: shuzhengkangxun)

Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE

Visit HPA-China’s Information Hub, HERE